CRISPR Therapeutics (CRSP) Competitors $38.67 +1.27 (+3.40%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRSP vs. MRNA, EXEL, NBIX, QGEN, RGEN, TECH, RVMD, HALO, ADMA, and KRYSShould you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Moderna (MRNA), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Qiagen (QGEN), Repligen (RGEN), Bio-Techne (TECH), Revolution Medicines (RVMD), Halozyme Therapeutics (HALO), ADMA Biologics (ADMA), and Krystal Biotech (KRYS). These companies are all part of the "biological products, except diagnostic" industry. CRISPR Therapeutics vs. Moderna Exelixis Neurocrine Biosciences Qiagen Repligen Bio-Techne Revolution Medicines Halozyme Therapeutics ADMA Biologics Krystal Biotech Moderna (NASDAQ:MRNA) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Is MRNA or CRSP more profitable? Moderna has a net margin of -110.04% compared to CRISPR Therapeutics' net margin of -981.54%. CRISPR Therapeutics' return on equity of -18.46% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-110.04% -28.74% -21.83% CRISPR Therapeutics -981.54%-18.46%-15.79% Which has better earnings and valuation, MRNA or CRSP? CRISPR Therapeutics has lower revenue, but higher earnings than Moderna. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.20B3.45-$3.56B-$9.28-3.08CRISPR Therapeutics$35M95.42-$366.25M-$4.37-8.85 Do insiders and institutionals believe in MRNA or CRSP? 75.3% of Moderna shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 11.0% of Moderna shares are owned by company insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor MRNA or CRSP? CRISPR Therapeutics received 266 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 64.48% of users gave CRISPR Therapeutics an outperform vote while only 53.62% of users gave Moderna an outperform vote. CompanyUnderperformOutperformModernaOutperform Votes21553.62% Underperform Votes18646.38% CRISPR TherapeuticsOutperform Votes48164.48% Underperform Votes26535.52% Which has more volatility and risk, MRNA or CRSP? Moderna has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Do analysts recommend MRNA or CRSP? Moderna currently has a consensus target price of $58.70, indicating a potential upside of 105.68%. CRISPR Therapeutics has a consensus target price of $73.11, indicating a potential upside of 89.05%. Given Moderna's higher possible upside, equities analysts plainly believe Moderna is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04CRISPR Therapeutics 1 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.48 Does the media favor MRNA or CRSP? In the previous week, Moderna had 18 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 28 mentions for Moderna and 10 mentions for CRISPR Therapeutics. Moderna's average media sentiment score of 0.98 beat CRISPR Therapeutics' score of 0.79 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 18 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryModerna beats CRISPR Therapeutics on 10 of the 19 factors compared between the two stocks. Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRSP vs. The Competition Export to ExcelMetricCRISPR TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.34B$3.00B$5.57B$7.83BDividend YieldN/A1.89%5.11%4.21%P/E Ratio-8.8530.4222.4418.48Price / Sales95.42498.92394.10103.59Price / CashN/A168.6838.1834.62Price / Book1.723.206.774.25Net Income-$366.25M-$72.35M$3.22B$248.23M7 Day Performance-1.13%1.46%1.48%0.89%1 Month Performance16.69%8.79%3.99%3.53%1 Year Performance-28.14%-22.36%16.20%5.08% CRISPR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRSPCRISPR Therapeutics2.7944 of 5 stars$38.67+3.4%$73.11+89.0%-27.0%$3.34B$35M-8.85473Upcoming EarningsMRNAModerna4.3377 of 5 stars$27.39+0.6%$58.70+114.3%-74.1%$10.59B$3.20B-2.953,900Upcoming EarningsEXELExelixis4.0788 of 5 stars$38.24+2.2%$37.59-1.7%+66.9%$10.54B$2.17B21.601,220Short Interest ↑Analyst RevisionPositive NewsNBIXNeurocrine Biosciences4.8613 of 5 stars$105.50-1.2%$160.90+52.5%-21.7%$10.43B$2.36B32.041,200Upcoming EarningsAnalyst ForecastAnalyst RevisionQGENQiagen3.6718 of 5 stars$42.23+0.4%$47.83+13.3%+4.0%$9.39B$1.98B117.586,030Upcoming EarningsAnalyst RevisionNews CoverageRGENRepligen4.8875 of 5 stars$142.39-1.6%$176.82+24.2%-16.0%$8.01B$634.44M-279.712,020Earnings ReportAnalyst UpgradeNews CoveragePositive NewsTECHBio-Techne4.828 of 5 stars$50.12-0.2%$81.14+61.9%-20.3%$7.92B$1.20B50.633,000RVMDRevolution Medicines3.7684 of 5 stars$41.45+6.9%$66.67+60.8%+8.3%$7.71B$742,000.00-11.55250Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsHALOHalozyme Therapeutics4.0044 of 5 stars$60.20-0.5%$62.89+4.5%+61.2%$7.44B$1.02B17.55390Upcoming EarningsInsider TradeAnalyst RevisionADMAADMA Biologics1.481 of 5 stars$24.17+10.6%$22.50-6.9%+265.0%$5.73B$426.45M86.09530Upcoming EarningsNews CoveragePositive NewsGap DownHigh Trading VolumeKRYSKrystal Biotech4.9031 of 5 stars$168.65+0.3%$222.71+32.1%+10.9%$4.88B$290.52M56.43210Upcoming EarningsAnalyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies Moderna Alternatives Exelixis Alternatives Neurocrine Biosciences Alternatives Qiagen Alternatives Repligen Alternatives Bio-Techne Alternatives Revolution Medicines Alternatives Halozyme Therapeutics Alternatives ADMA Biologics Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRSP) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRSP Stock Free CRSP Stock Alerts